



n e x y[®]

CAPTURE CRYSTAL CLEAR RETINAL
IMAGES IN A FULLY AUTOMATIC WAY

VISIONIX
The Vision of the Future





Nexy: retinal screening at a glance

- Fully automated
- Meets social distancing guidelines
- AI compatible



Exclusive technology

Nexy utilises an innovative cross-polarized light technology that provides excellent image quality while maintaining a compact footprint.



AMD

**Diabetic
Retinopathy**

**Epiretinal
Membrane**

Glaucoma


NEXY

VALUE-ADDED FEATURES

- Robotic movements: auto-alignment, autofocus and auto-capture. Just press Start and Nexy does the rest
- Automatic capture of high-quality images for detailed screening and evaluation with minimal personal training
- Pleasant aesthetic: small footprint and ergonomic design
- Modern gesture interaction: the intuitive interface facilitates a quick start and smooth navigation
- Review images from a local PC (in .DCM format as well as jpg/png format) or from an intranet PC
- Review images from the Next Sight website using a personal and secure account
- Teamviewer application for remote assistance



Way to share images



Protection of patient data

Nexy is GDPR compliant.

Patient sensitive data is secure thanks to client-side data encryption. This means that patient data is encrypted on the sender's side, before it is transmitted to a server such as a cloud storage service.

This client-side encryption guarantees secure privacy and GDPR compliance.

n e x y[®]

TECHNICAL SPECIFICATIONS

HARDWARE SPECIFICATION

Field of view	45°
Field of view with mosaic function	90°
Retinal resolution	14 microns
Fixations	7 fixations set-ups
Tablet dimensions	10.4"
Weight	32,4 lbs
Size	13,4 x 16,9 x 18,1 in.

SOFTWARE SPECIFICATION

Image filters (vascular, choroidal, nerve fibre, red free)
Cup-to-disc ratio for glaucoma screening
Automatic mosaic function
Shared intranet folder
DICOM standard compatible
Fundus adapter to transfer images to a local pc



DATA MANAGEMENT

Full AI integration (option)
Cloud-based secure storage
Client-side data encryption
Automatic database backup
Review images from the password protected website, a network shared folder or a local PC
Multilevel account
Access by personal user



WIRELESS
REMOTE
CONTROL



NEXY meets social
distancing guidelines



ABOUT US

The Luneau Technology group, bringing together the Visionix®, Briot® and Weco® brands, is a major force in the market, with a range of equipment to cover all the Eye Care Professionals' requirements: Refraction and ophthalmic diagnosis, lens inspection in industrial production and lens cutting in the optician's lab.

Our aim has always been to provide you with the latest technologies to permit quicker screening for visual disorders and provide a better quality of life, with ever more effective equipment. Our aim is to provide innovative and increasingly efficient technologies that allow you to rapidly screen for visual disorders, providing your patients with a better quality of life



n e x y[®]



Luneau Technology

LUNEAU TECHNOLOGY OPERATIONS

2 Rue Roger Bonnet-27340 PONT DE L'ARCHE - FRANCE - Tel. + 33 232 989 132 - Fax + 33 235 020 294
contact@luneautech.com - www.luneautech.com



THE NEXY A.I. SOLUTION

THE NEXT STEP IN VISUAL HEALTH

A combination of an automated fundus camera and dedicated A.I. solution, that delivers extensive retinal health assessments in under 5-minutes.

n e x y[®]

VISIONIX

13 IN 1 Key retinal pathologies

World Health Organization:

Globally, at least

1 BILLION

PEOPLE HAVE VISION IMPAIRMENT

which could have been prevented or has yet to be addressed.¹

This includes approximately

3 MILLION

PEOPLE WITH DIABETIC RETINOPATHY

a common retinal pathology.¹

n e x y[®]

- Diabetic retinopathy
- Retinal vessel occlusion
- Pathologic myopia
- Exudative ARMD
- Retinitis pigmentosa
- Nonexudative ARMD
- Epiretinal membrane
- Optic disc atrophy
- Central serous chorioretinopathy
- Suspicious glaucoma
- Macular hole
- Retinal detachment
- Retinal artery occlusion




As a consultant ophthalmologist I welcome A.I. technology. It is clear that A.I. has a major contribution to make in the identification of retinal disease.



Dr. Eugenio Innocenti
Consultant Ophthalmologist (Dusseldörf)

CHAMPIONING VISUAL HEALTH

The NEXY A.I solution allows you to expand your visual health offering. By playing an active role in retinal screening, you can support the health of your community and enhance your customer experience.



PARTNERSHIP IN ACTION

As a NEXY A.I. innovation partner, you will receive service training, sales guidance and ongoing support from Luneau Technology.

EXTENSIVE SCREENING



STEP 1:

Fully automated fundus camera



STEP 2:

Secured data transfer and encryption



STEP 3:

Dedicated A.I. analysis



STEP 4:

Detailed report



Start to finish in 5 minutes



The most important thing with retinal disease is to catch it as early as possible. Any technology or solution that supports that goal can help improve patient outcomes, and has an important role to play in visual health.



Dr. Eugenio Innocenti
Consultant Ophthalmologist (Dusseldörf)

EXPERT VALIDATED

Reports validated
against expert
assessment

CE CERTIFIED

Class III
registered A.I. with
CE certification

ESTABLISHED QUALITY

>90% sensitivity
and specificity with
low risk of false
results*

VALIDATED SOLUTION

The NEXY A.I. solution covers 13 common retinal pathologies.

With most retinal diseases, the primary goal of treatment is to slow disease progression and preserve the retina and associated vision.

Sensitivity

The ability of the A.I. to correctly tag a positive result

93%*

Specificity

The ability of the A.I. to correctly tag a negative result

90.6%*

The NEXY camera utilises an innovative cross-polarized light technology that provides excellent image quality while maintaining a compact footprint.

- Robotic movements: auto-alignment, auto-focus and auto-capture
- Automatic capture of high-quality images
- Pleasant aesthetic: small footprint and ergonomic design
- Modern gesture interaction: the intuitive interface facilitates a quick start and smooth navigation



*Internal study for CE mark submission by Li B, Chen H, Zhang B based on 3,127 images collected between 2014 and 2018, China, Visionary Intelligence.

The clinical study was executed in medical environment in ideal circumstances. Accuracy might differ depending on the measurement conditions.



References:

1. World Health Organization. World Report on Vision. Available at: <https://www.who.int/publications/i/item/9789241516570>

Abbreviations:

A.I., artificial intelligence; ARMD, age-related macular degeneration

Any indications are partial and provided by an artificial intelligence software. Artificial intelligence software analysis is not a replacement for diagnosis made by an ophthalmologist. It is intended only to retrieve particular features in the portion of the retina examined. NEXY processes pictures taken on a limited portion of the retina. Even if abnormal defaults are not detected, this does not guarantee the absence of the disease.

Luneau Technology Operations.

2 rue Roger Bonnet, 27340 Pont-de-l'Arche. France.
+33 2 32 98 91 32.


The Nexy is a non-mydiatic retinograph that allows the observation, capture and recording of very high definition images without dilating the fundus through the pupil. Class IIa medical device / EC Declaration of Conformity. The information in this document is intended for use by visual health professionals. Read the instructions for use carefully before use. Nexy training is required before use. Examination covered by health insurance under certain conditions. Manufactured by: Next Sight a Luneau Technology company - Distributed by Luneau Technology Germany

Nexy AI software is a cloud-based artificial intelligence fundus image analysis software provided by Visionary Intelligence that allows to automatically detect signs of more than 12 different retinal pathologies on Nexy images. The indications given by the software are provisional, partial and based on a limited portion of the retina. Class III medical device / EC Declaration of Conformity. Nexy AI software is indicated for use with the Nexy platform.

Patient Name: **MALESCU TOMAS**
ID: **ER_606_1639644048982**

Birth date: **13/10/1989**
Gender: **M**

SCREENING RESULT ON FUNDUS



There is a risk/suspect of **Exudative AMD, Nonexudative AMD and Central Serous Chorioretinopathy**.

No detected risk of retinal pathologies

Risk score

Exudative AMD	1/10
Nonexudative AMD	1/10
Central Serous Chorioretinopathy	1/10

Scan here to discover more about your retinal health




The images were analyzed based on the 13 most common retinal pathologies

INDICATIONS

It is advisable to refer to an ophthalmologist. The result of the AI software shows suspect/risk of anomalies in the portion of the posterior pole analyzed. Periodic appointments with an ophthalmologist helps to prevent retinal diseases that might cause vision damages.

The indications given are partial and provided by an artificial intelligence software. Artificial intelligence software analysis is not a replacement of a diagnosis made by an ophthalmologist but it is intended only to retrieve particular features in the portion of the fundus examined. The software processes pictures taken on limited portion of retina. Even if anomalous features are not retrieved by the software, this does not guarantee the absence of the disease.





Outcome of the AI screening is given with a traffic light **color code**:

- Risk of retinal detachment
Red alert is given only in case of suspect of retinal detachment.
- Risk of one or more retinal conditions
- No detected risk of retinal conditions

If one or more retinal conditions are detected, we highlight the **risk** for each of them with a **score** from 1 (the lowest) to 10 (the highest).

Risk score is meant to be an indicator of likelihood of the condition.

AI screening is not a medical diagnosis